Recent multicenter research showed a 22 percent improvement in the detection of fetal anomalies with the Sonio Suspect AI-powered ultrasound module.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Sonio Suspect, an artificial intelligence (AI)-enabled module that reportedly facilitates enhanced ultrasound detection of fetal anomalies.
Approximately 51 percent of fetal anomalies are not detected during conventional prenatal ultrasound screenings, according to Sonio, the developer of the Sonio Suspect software. The company says Sonio Suspect provides automated detection of eight ultrasound findings of fetal abnormalities across the heart, brain, and abdomen.
In a recent 47-facility multicenter study, Sonio said the Sonio Suspect module achieved a 91 percent area under the receiver operating characteristic curve (AUC) for fetal anomaly detection. (Image courtesy of Sonio.)
In a recent 47-facility multicenter study, Sonio said the Sonio Suspect module achieved a 91 percent area under the receiver operating characteristic curve (AUC) for fetal anomaly detection, a 22 percent improvement over unassisted interpretation. The company said the improved detection with Sonio Suspect was consistent regardless of clinician experience or background.
“By combining real-time AI quality control with AI-driven anomaly detection, Sonio supports ultrasound providers from exhaustive documentation to accurate diagnosis,” noted Cecile Brosset, the CEO and co-founder at Sonio. “Our technology is designed to help health-care providers detect issues early and streamline processes, ultimately improving the care every patient receives.”
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.